A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 1, 2006, Pages 254-262

  Borges, Luis ^a   Rex, Karen L ^a   Chen, Jennifer N ^a   Wei, Ping ^a   Kaufman, Stephen ^a   Scully, Sheila ^a   Pretorius, James K ^a   Farrell, Catherine L ^a  

^a AMGEN INC   (United States)

Author keywords

Epithelial thickness; Keratinocyte growth factor; Ki 67; Oral mucositis; Salivary gland

Indexed keywords

BIOLOGICAL ORGANS; CELLS; CHEMOTHERAPY;

EPITHELIAL THICKNESS; KERATINOCYTE GROWTH FACTOR; KI-67; ORAL MUCOSITIS; SALIVARY GLAND;

RADIOTHERAPY;

CISPLATIN; FLUOROURACIL; KERATINOCYTE GROWTH FACTOR RECEPTOR; PALIFERMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SCREENING; DRUG USE; EPITHELIUM CELL; ESOPHAGUS; FEMALE; HEAD AND NECK CANCER; INJECTION; INTESTINE MUCOSA; MOUSE; MOUTH MUCOSA; MUCOSA INFLAMMATION; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; RISK ASSESSMENT; SALIVARY GLAND; SALIVARY GLAND DISEASE; SMALL INTESTINE; THICKNESS; TONGUE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; CELL DIVISION; CISPLATIN; ESOPHAGUS; FEMALE; FIBROBLAST GROWTH FACTOR 7; HUMANS; JEJUNUM; KI-67 ANTIGEN; MICE; MOUTH; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMATITIS;

EID: 33746820230     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.025     Document Type: Article

References (53)

1. Sonis S.T. 2000, Oral complications. In: Holland J.F., Frei III E., and Bast Jr. R.C. (Eds). Cancer medicine (2000), BC Decker Inc, Philadelphia 2371-2379
2. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19 (2001) 2201-2205
3. Rose-Ped A.M., Bellm L.A., Epstein J.B., et al. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs 25 (2002) 461-467
4. Woo SB, Treister N. Chemotherapy-induced oral mucositis. Available online at http://www.emedicine.com/derm/topic682.htm. Accessed February 12, 2004
5. Elting L.S., Bodey G.P., and Keefe B.H. Septicemia and shock syndrome due to viridans streptococci. A case control study of predisposing factors. Clin Infect Dis 14 (1992) 1201-1207
6. Ruescher T.J., Sodeifi A., Scrivani S.J., et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82 (1998) 2275-2281
7. Rapaport A.P., Miller Watelet L.F., Linder T., et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17 (1999) 2446-2453
8. Bensadoun R.-J., Magne N., Marcy P.-Y., et al. Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients. New trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol 258 (2001) 481-487
9. Armstrong T.S. Stomatitis in the bone marrow transplant patient. An overview and proposed oral care protocol. Cancer Nurs 17 (1994) 403-410
10. Donnelly J.P., Blijlevens N.M.A., and Verhagen C.A. Can anything be done about oral mucositis?. Ann Oncol 14 (2003) 505-507
11. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 (2004) 2026-2046
12. Plevova P. Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis. A review. Oral Oncol 35 (1999) 453-470
13. Worthington H.V., and Clarkson J.E. Prevention of oral mucositis and oral candidiasis for patients with cancer treated with chemotherapy. Cochrane systematic review. J Dent Educ 66 (2002) 903-911
14. Antonadou D., Pepelassi M., Synodinou M., et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 739-747
15. Antonadou D., Petridis A., Synodinou M., et al. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol 30 (2003) 2-9
16. Castagna L., Benhamou E., Pedraza E., et al. Prevention of mucositis in bone marrow transplantation. A double blind randomised controlled trial of sucralfate. Ann Oncol 12 (2001) 953-955
17. Anderson P.M., Schroeder G., and Skubitz K.M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83 (1998) 1433-1439
18. Skubitz K.M., and Anderson P. Oral glutamine to prevent chemotherapy induced stomatitis. A pilot study. J Lab Clin Med 127 (1996) 223-228
19. Dazzi C., Cariello A., Giovanis P., et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue. A double blind, randomized, placebo-controlled study. Ann Oncol 14 (2003) 559-563
20. Guo H., Seixas-Silva Jr. J.A., Epperly M.W., et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of human manganese superoxide dismutase (SOD2). Radiat Res 159 (2003) 361-370
21. Finch P.W., Rubin J.S., Miki T., et al. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 245 (1989) 752-755
22. Rubin J.S., Bottaro D.P., Chedid M., et al. Keratinocyte growth factor. Cell Biol Int 19 (1995) 399-411
23. Alarid E.T., Rubin J.S., Young P., et al. Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc Natl Acad Sci U S A 91 (1994) 1074-1078
24. Houseley R.M., Morris C.F., Boyle W., et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 94 (1994) 1764-1777
25. Pierce G.F., Yanagihara D., Klopchin K., et al. Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J Exp Med 179 (1994) 831-840
26. Ulich T.R., Yi E.S., Cardiff R., et al. Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor. Am J Pathol 144 (1994) 862-868
27. Ulich T.R., Yi E.S., Longmuir K., et al. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 93 (1994) 1298-1306
28. Yi E.S., Yin S., Harclerode D.L., et al. Keratinocyte growth factor induces pancreatic ductal epithelial proliferation. Am J Pathol 145 (1994) 80-85
29. Farrell C.L., Bready J.V., Rex K.L., et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58 (1998) 933-939
30. Farrell C.L., Rex K.L., Chen J.N., et al. The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 35 (2002) 78-85
31. Dorr W., Noack R., Spekl K., et al. Modification of oral mucositis by keratinocyte growth factor. Single radiation exposure. Int J Radiat Oncol Biol Phys 77 (2001) 341-347
32. Dorr W., Spekl K., and Farrell C.L. Amelioration of acute oral mucositis by keratinocyte growth factor. Fractionated irradiation. Int J Radiat Oncol Biol Phys 54 (2002) 245-251
33. Farrell C.L., Rex K.L., Kaufman S.A., et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 75 (1999) 609-620
34. Meropol N.J., Somer R.A., Gutheil J., et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy. Potential role as mucosal protectant. J Clin Oncol 21 (2003) 1452-1458
35. Rubin J.S., Osada H., Finch P.W., et al. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A 86 (1989) 802-806
36. Marcu L., Van Doorn T., and Olver I. Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer-A review of their cooperation. Acta Oncol 42 (2003) 315-325
37. Shoker B.S., Jarvis C., Davies M.P., et al. Immunodetectable cyclin D(1) is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer 84 (2001) 1064-1069
38. Xin W., Paulino A.F., Xin W., and Paulino A.F. Prognostic factors in malignant mixed tumors of the salivary gland. Correlation of immunohistochemical markers with histologic classification. Ann Diagnost Pathol 6 (2002) 205-210
39. Boland G.P., Butt I.S., Prasad R., et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90 (2004) 423-429
40. Wilcox J.N. Fundamental principles of in situ hybridization. J Histochem Cytochem 41 (1993) 1725-1733
41. MacMillan C.H., Carrick K., Bradley P.J., et al. Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck. Br J Radiol 64 (1991) 941-946
42. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. New Engl J Med 338 (1998) 1798-1804
43. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer. A randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
44. Vokes E.E., Kies M.S., Haraf D.J., et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 18 (2000) 1652-1661
45. Denis F., Garaud P., Bardet E., et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma. Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55 (2003) 93-98
46. Nagy B., Molnar J., Rovo L., et al. Effective chemoradiotherapy without additive toxicity in locoregionally advanced head and neck cancer. Anticancer Res 23 (2003) 4329-4332
47. National Cancer Institute. Oral complications of chemotherapy and head/neck radiation (2004). http://www.cancer.gov/cancerinfo/pdq/supportivecare/oralcomplications/Healthprofessional Available online at: http://www.cancer.gov/cancerinfo/pdq/supportivecare/oralcomplications/Healthprofessional. Accessed April 29, 2004
48. Cox J.D., Pajak T.F., Marcial V.A., et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the respiratory/digestive tracts. New evidence for accelerated proliferation from RTOG Protocol 83-13. Cancer 69 (1992) 2744-2748
49. Budman D.R., Berry D.A., Cirrincione C.T., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90 (1998) 1205-1211
50. Lee K.-W., Kim D.-Y., Yun T., et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients. comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 98 (2003) 2651-2656
51. Epstein J.B., and Schubert M.M. Oropharyngeal mucositis in cancer therapy-Review of pathogenesis, diagnosis and management. Oncology 17 (2003) 1767-1779
52. Shih A., Miaskowski C., Dodd M.J., et al. Mechanisms for radiation-induced oral mucositis and the consequences. Cancer Nurs 26 (2003) 222-229
53. LaRochelle W.J., Sakaguchi K., Atabey N., et al. Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. Biochemistry 38 (1999) 1765-1771